• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Thomas W. Martens, MD: MOBILE Study Findings on CGM vs BGM in T2 Diabetes


MOBILE study lead author Thomas W. Martens, MD, discusses results of the study which was designed to capture CGM results in real-world primary care practice.

In adults with poorly controlled type 2 diabetes (T2D) treated with basal but not prandial insulin, use of real time continuous glucose monitoring (rtCGM) compared to standard blood glucose monitoring (BGM) significantly improved glycemic control and time in target glucose range.

These are topline results from the recently published MOBILE study, the only study to date to evaluate use of rtCGM in patients with T2D not using multiple daily injections (MDI) of insulin.

The MOBILE findings are notable for primary care clinicians for several reasons. Most critically, the study recruited participants from primary care practices specifically to create a cohort reflective of the real world where up to 80% of diabetes patients receive care from a primary provider. The strategy also ensured a diverse population--more than half of participants were nonwhite.

Patient Care® Online recently spoke with MOBILE lead investigator Thomas W. Martens, MD, for an in-depth review of the study concept and a close look at the results.

Thomas W. Martens, MD, is a director at the Park Nicollet International Diabetes Center, an affiliate of Health Partners Institute in Minneapolis, Minnesota.

For additional interviews with Dr Martens on the MOBILE Study, please see:

CGM vs SMBG in Primary Care: What Does the T2D Evidence Say?

Tom Martens, MD, Talks about the Vision for CGM as Part of Primary Care for Type 2 Diabetes

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.